Results 11 to 20 of about 3,148 (231)

Lipoprotein apheresis to treat elevated lipoprotein (a). [PDF]

J Lipid Res, 2016
An elevated plasma concentration of lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. Life style modification and currently available drugs either fail to effectively lower plasma Lp(a) levels or do not result in clinical benefit. However, lipoprotein apheresis is very efficient in decreasing Lp(a) concentrations.
Waldmann E, Parhofer KG.
europepmc   +5 more sources

Is it possible to regress atherosclerotic lesions with long-term treatment with lipoprotein apheresis?

Российский кардиологический журнал
The article presents the up-to-date information on the effect of lipoprotein apheresis (LA) on atherosclerotic lesions. Some studies using modern diagnostic imaging techniques (such as intravascular ultrasound or magnetic resonance imaging) have clearly ...
Ulrich Julius, Sergey Tselmin, V. A. Korneva   +2 more
doaj   +2 more sources

Homozygous familial hypercholesterolemia with stenosis of the left anterior descending coronary artery successfully treated with weekly low‐density lipoprotein apheresis for 16 years without percutaneous coronary intervention [PDF]

Clinical Case Reports, 2019
We successfully treated a patient with homozygous familial hypercholesterolemia (HoFH) with stable coronary arterial disease using optimal medical therapy and low‐density lipoprotein (LDL) apheresis for 16 years without percutaneous coronary intervention
Takanori Yasu, Masahiro Shimoyama, Hiroshi Wada, Tomohiro Iwakura, Shigeru Toyoda, Atsuhiko Kawabe, Takushi Sugiyama   +6 more
doaj   +2 more sources

Preoperative Low-Density Lipoprotein Apheresis for Preventing Recurrence of Focal Segmental Glomerulosclerosis after Kidney Transplantation [PDF]

Journal of Transplantation, 2018
Background. Focal segmental glomerulosclerosis (FSGS) often develops rapidly and frequently progresses to renal failure, while the recurrence rate after kidney transplantation is 20–50%.
Akihito Sannomiya, Toru Murakami, Ichiro Koyama, Kosaku Nitta, Ichiro Nakajima, Shohei Fuchinoue   +5 more
doaj   +2 more sources

Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events? [PDF]

Journal of Cardiovascular Development and Disease, 2020
Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)).
Ulrich Julius, Solveig Kuss, Sergey Tselmin, Ulrike Schatz, Stefan R. Bornstein   +4 more
doaj   +2 more sources

Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study [PDF]

Frontiers in Pediatrics, 2019
Background: Focal segmental glomerulosclerosis (FSGS) causes end stage renal disease (ESRD) in significant proportion of patients worldwide. Primary FSGS carries poor prognosis and management of FSGS patients, refractory to standard treatments or ...
Rupesh Raina, Rupesh Raina, Vinod Krishnappa, Vinod Krishnappa, Cheryl Sanchez-Kazi, Alejandro Quiroga, Katherine E. Twombley, Robert Mathias, Megan Lo, Ronith Chakraborty, Shefali Mahesh, Julia Steinke, Timothy Bunchman, Joshua Zaritsky   +13 more
doaj   +2 more sources

Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia. [PDF]

J Clin Lab Anal, 2020
Wen J, Dong Q, Liu G, Gao Y, Li XL, Jin JL, Li JJ, Guo YL.   +7 more
europepmc   +3 more sources

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions. [PDF]

Oxid Med Cell Longev, 2020
Mickiewicz A, Kreft E, Kuchta A, Wieczorek E, Marlęga J, Ćwiklińska A, Paprzycka M, Gruchała M, Fijałkowski M, Jankowski M.   +9 more
europepmc   +3 more sources

Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs. [PDF]

Int J Mol Sci
Krzesińska A, Marlęga-Linert J, Chyła-Danił G, Marcinkowska M, Rogowska P, Stumska K, Fijałkowski M, Gruchała M, Jankowski M, Mickiewicz A, Kuchta A.   +10 more
europepmc   +2 more sources

Current Role of Lipoprotein Apheresis. [PDF]

Curr Atheroscler Rep, 2019
Lipoprotein apheresis is a very efficient but time-consuming and expensive method of lowering levels of low-density lipoprotein cholesterol, lipoprotein(a)) and other apoB containing lipoproteins, including triglyceride-rich lipoproteins. First introduced almost 45 years ago, it has long been a therapy of "last resort" for dyslipidaemias that cannot ...
Thompson G, Parhofer KG.
europepmc   +7 more sources